

Original Manuscript

A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma

Matteo Giaccherini^{1,*} , Mariaconcetta Rende^{1,*}, Manuel Gentiluomo¹ , Chiara Corradi¹, Livia Archibugi^{2,3}, Stefano Ermini⁴, Evaristo Maiello⁵, Luca Morelli⁶, Casper H.J. van Eijck⁷, Giulia Martina Cavestro⁸, Marton Schneider⁹, Antanas Mickevicius¹⁰, Kestutis Adamonis¹¹, Daniela Basso¹², Viktor Hlavac¹³, Domenica Gioffreda¹⁴, Renata Talar-Wojnarowska¹⁵, Ben Schöttker^{16,17}, Martin Lovecek¹⁸, Giuseppe Vanella^{2,3}, Maria Gazouli¹⁹ , Miyuki Uno²⁰, Ewa Malecka-Wojcieszko¹⁵, Pavel Vodicka^{21,22} , Mara Goetz²³, Marteen F. Bijlsma^{24,25}, Maria Chiara Petrone³, Francesca Bazzocchi²⁶, Mindaugas Kiudelis¹⁰, Andrea Szentesi^{27,28,29,30}, Silvia Carrara³¹, Gennaro Nappo^{32,33}, Hermann Brenner^{16,34,35}, Anna Caterina Milanetto¹², Pavel Soucek¹³, Verena Katzke³⁶, Giulia Peduzzi¹, Cosmeri Rizzato¹, Claudio Pasquali¹², Xuechen Chen^{16,37} , Gabriele Capurso^{2,3}, Thilo Hackert⁹, Bas Bueno-de-Mesquita³⁸ , Faik G. Uzunoglu²³, Peter Hegyi^{27,28,29,39}, William Greenhalf⁴⁰, George E. Theodoropoulos⁴¹, Cosimo Sperti¹², Francesco Perri¹⁴, Martin Oliverius⁴², Andrea Mambriani⁴³, Francesca Tavano¹⁴, Riccardo Farinella¹, Paolo Giorgio Arcidiacono³, Maurizio Lucchesi⁴³, Stefania Bunduc^{27,29,39,44,45}, Juozas Kupcinskas¹¹, Gregorio Di Franco⁶, Hannah Stocker^{16,17}, John P. Neoptolemos⁹, Franco Bambi⁴, Krzysztof Jamrozak⁴⁶, Sabrina G.G. Testoni³, Mateus N. Aoki⁴⁷, Beatrice Mohelnikova-Duchonova⁴⁸, Jacob R. Izbicki²³, Raffaele Pezzilli⁴⁹, Rita T. Lawlor⁵⁰, Emanuele F. Kauffmann⁵¹, Evangelina López de Maturana⁵², Nuria Malats⁵² , Federico Canzian⁵³ , Daniele Campa^{1,*} 

¹Department of Biology, University of Pisa, Pisa, Italy

²Digestive and Liver Disease Unit, Sant'Andrea Hospital, Rome, Italy

³Pancreato-Biliary Endoscopy and Endosonography Division, Pancreas Translational and Clinical Research Center, IRSSC San Raffaele Scientific Institute, Milan, Italy

⁴Blood Transfusion Service, Azienda Ospedaliero Universitaria Meyer, Florence, Italy

⁵Department of Oncology, Fondazione IRCCS 'Casa Sollievo della Sofferenza' Hospital, San Giovanni Rotondo, Italy

⁶General Surgery Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy

⁷Department of Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands

⁸Gastrointestinal Endoscopy Unit, Vita-Salute San Raffaele University, IRCCS San Raffaele, Milan, Italy

⁹Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany

¹⁰Surgery Department, Lithuanian University of Health Sciences, Kaunas, Lithuania

¹¹Gastroenterology Department, Lithuanian University of Health Sciences, Kaunas, Lithuania

¹²Department of Surgery, Oncology and Gastroenterology-DiSCOG, University of Padova, Padua, Italy

¹³Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic

¹⁴Division of Gastroenterology and Research Laboratory, Fondazione IRCCS 'Casa Sollievo della Sofferenza' Hospital, San Giovanni Rotondo, Italy

¹⁵Department of Digestive Tract Diseases, Medical University of Lodz, Lodz, Poland

¹⁶Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany

¹⁷Network Aging Research (NAR), Heidelberg University, Heidelberg, Germany

¹⁸Department of Surgery I, University Hospital Olomouc, Olomouc, Czech Republic

¹⁹Department of Basic Medical Sciences, Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Athens, Greece

²⁰Center for Translational Research in Oncology (LIM24), Instituto Do Câncer Do Estado de São Paulo, (ICESP), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, Brazil

- ²¹Institute of Experimental Medicine, Czech Academy of Science, Prague, Czech Republic
- ²²Institute of Biology and Medical Genetics, 1st Medical Faculty, Charles University in Prague, Prague, Czech Republic
- ²³Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- ²⁴Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam UMC and Cancer Center Amsterdam, Amsterdam, The Netherlands
- ²⁵Onco Institute, Amsterdam, The Netherlands
- ²⁶Department of Surgery, Fondazione IRCCS 'Casa Sollievo della Sofferenza' Hospital, San Giovanni Rotondo, Italy
- ²⁷Medical School, Institute for Translational Medicine, University of Pécs, Pécs, Hungary
- ²⁸János Szentágothai Research Center, University of Pécs, Pécs, Hungary
- ²⁹Center for Translational Medicine, Semmelweis University, Budapest, Hungary
- ³⁰Centre for Translational Medicine, Department of Medicine, University of Szeged, Szeged, Hungary
- ³¹Digestive Endoscopy Unit, Division of Gastroenterology, Humanitas Clinical and Research Center IRCCS, Milan, Italy
- ³²Pancreatic Unit, Humanitas Clinical and Research Center IRCCS, Milan, Italy
- ³³Department of Biomedical Sciences, Humanitas University, Milan, Italy
- ³⁴Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany
- ³⁵German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
- ³⁶Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- ³⁷Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany
- ³⁸Centre for Nutrition, Prevention and Health Services, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
- ³⁹Division of Pancreatic Diseases, Heart and Vascular Center, Semmelweis University, Budapest, Hungary
- ⁴⁰Institute for Health Research Liverpool Pancreas Biomedical Research Unit, University of Liverpool, Liverpool, United Kingdom
- ⁴¹First Department of Propaedeutic Surgery, Hippocraton General Hospital, National and Kapodistrian University of Athens, Athens, Greece
- ⁴²Surgery Clinic Third Faculty of Medicine, Charles University, Prague, Czech Republic
- ⁴³Oncological Department Massa Carrara, Azienda USL Toscana Nord Ovest, Carrara, Italy
- ⁴⁴Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
- ⁴⁵Fundeni Clinical Institute, Bucharest, Romania
- ⁴⁶Department of Hematology, Transplantology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland
- ⁴⁷Laboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz), Curitiba, Brazil
- ⁴⁸Department of Oncology, Palacky University Olomouc, Olomouc, Czech Republic
- ⁴⁹County Medical Association of Potenza, Potenza, Italy
- ⁵⁰ARC-NET: Centre for Applied Research on Cancer, University and Hospital Trust of Verona, Verona, Italy
- ⁵¹Division of General and Transplant Surgery, Pisa University Hospital, Pisa, Italy
- ⁵²Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
- ⁵³Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany
- †These authors share the first position.
- *Corresponding author: Department of Biology, University of Pisa, Via Derna 1, 56126 Pisa, Italy. E-mail: daniele.campa@unipi.it

Abstract

Pleiotropic variants (i.e. genetic polymorphisms influencing more than one phenotype) are often associated with cancer risk. A scan of pleiotropic variants was successfully conducted 10 years ago in relation to pancreatic ductal adenocarcinoma susceptibility. However, in the last decade, genetic association studies performed on several human traits have greatly increased the number of known pleiotropic variants. Based on the hypothesis that variants already associated with a least one trait have a higher probability of association with other traits, 61 052 variants reported to be associated by at least one genome-wide association study with at least one human trait were tested in the present study consisting of two phases (discovery and validation), comprising a total of 16 055 pancreatic ductal adenocarcinoma (PDAC) cases and 212 149 controls. The meta-analysis of the two phases showed two loci (10q21.1-rs4948550 ($P = 6.52 \times 10^{-5}$) and 7q36.3-rs288762 ($P = 3.03 \times 10^{-5}$) potentially associated with PDAC risk. 10q21.1-rs4948550 shows a high degree of pleiotropy and it is also associated with colorectal cancer risk while 7q36.3-rs288762 is situated 28,558 base pairs upstream of the Sonic Hedgehog (*SHH*) gene, which is involved in the cell-differentiation process and PDAC etiopathogenesis. In conclusion, none of the single nucleotide polymorphisms (SNPs) showed a formally statistically significant association after correction for multiple testing. However, given their pleiotropic nature and association with various human traits including colorectal cancer, the two SNPs showing the best associations with PDAC risk merit further investigation through fine mapping and ad hoc functional studies.

Keywords: pleiotropy; pancreatic cancer; single nucleotide polymorphism; genetic susceptibility

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is a relatively rare disease with a crude incidence rate of 18.7 per 100 000 individuals per year in Europe [1]. Only a small number of potential PDAC risk factors have been identified, such as cigarette smoking, type 2 diabetes mellitus, chronic pancreatitis, overweight, and non-O blood groups [2–4]. Recently a study carried out in the context of UK Biobank (UKBB) has suggested stress as a major contributor to the development of the disease [5]. The genetic susceptibility to PDAC is due to rare high-penetrance mutations and common low-penetrance gen-

etic variants, that alone or in combination are associated with increased risk of developing PDAC [6–24]. However, PDAC is a polygenic and complex multifactorial disease that shares a portion of the genetic background with several human traits [25,26]. For example, the *TERT-CLPTM1L* region is known to be associated with PDAC risk, but it is also associated with risk of melanoma, breast, and cervical cancers [26]. A genetic variant independently associated with more than one trait is defined as pleiotropic, a characteristic shared by many risk loci for a large number of human traits [27]. Pleiotropic polymorphisms could have a crucial role in the genetic architecture of complex diseases due to their influence on

different pathways and biological mechanisms [28–30]. Pleiotropic single nucleotide polymorphisms (SNPs) are common in cancer, and there are regions in the genome called ‘nexus’ that are associated with more than one type of cancer [31,32]. In addition, several PDAC risk loci are also associated with non-cancer phenotypes. For example, *ABO* and *TERT* SNPs are associated with a plethora of human traits, such as longevity [33], type II diabetes [34], male infertility [35], mitochondrial DNA copy number [36], and high-density lipoprotein cholesterol level [37]. Therefore, the study of pleiotropic SNPs could be instrumental in unravelling the genetic architecture of human diseases, as SNPs that are already associated with one trait have an increased chance of being associated with other phenotypes. The analysis of the possible association of pleiotropic variants with PDAC was completed in a study comprising 1087 SNPs in 2857 PDAC cases and 2967 controls, in which the authors identified, for the first time, a new PDAC risk locus (rs7310409) in the *HNF1A* homeobox A (*HNF1A*) gene [38]. In the decade since that study, our knowledge of SNP-phenotype associations has greatly increased. With these premises, we aimed to identify novel pleiotropic SNPs associated with PDAC risk in an extensive multi-ethnic study of 16 880 PDAC cases and 219 861 controls.

Material and methods

Study design

The present study was carried out in two phases. First, a discovery phase where pleiotropic SNPs reported to be associated with at least one human trait were tested for association in a case-control study consisting of 8738 PDAC cases and 7034 controls. The discovery phase consisted of the PanScan I, II, III [9,11,12], and PanC4 studies [14] that were imputed separately and then merged and analysed together. After the discovery phase two rounds of replication were carried out, the first (replication1) consisting of the European Study into Digestive Illnesses and Genetics (PanGenEU) study [39] and the second (replication2) consisting of the Pancreatic Disease Research (PANDoRA) consortium [24], the Japan Pancreatic Cancer Research Consortium (JaPAN) [7,10,40,41], and FinnGen [42]. Replication 2 was carried out in all SNPs that were significant in the discovery and

replication 1 phases. Table 1 shows the number of cases and controls analysed in each dataset, alongside age, and sex distribution.

Discovery phase

A list of SNPs associated with at least one human trait at genome-wide significance level ($P < 5 \times 10^{-8}$) was obtained from the GWAS Catalog portal. The list contained 126 080 SNP-trait associations, consisting of 73 700 unique SNPs, among which 1869 did not have reference SNP ID number (rs#) and therefore were not included in the analyses. The list included SNPs associated with any disease and/or any trait and was not restricted by ethnicity. All the selected SNPs were analysed using the genotypes of the PanScan I, II, III, and PanC4 GWASs. The genotypes were downloaded from the database of genotypes and phenotypes (dbGaP; study accession nos. phs000206.v5.p3 and phs000648.v1.p1; project reference no. 12644). Genotyping and quality control details of these studies have been described in the original publications [9,11,12,14].

The four combined datasets included 9563 PDAC cases and 8073 controls. The genotypes were imputed using the Michigan Imputation Server (<https://imputationserver.sph.umich.edu>), and the Haplotype Reference Consortium (HRC, V.r1.1) as reference panel. The imputation for PanScan I, II, III, and PanC4 GWASs was carried out separately for each dataset.

Before imputation, the datasets were filtered applying the following quality controls: removal of individuals with sex mismatches, missing genotypes > 2%, relatedness issues (PL_HAT > 0.2), and minimal or excessive heterozygosity (> 3 SDs from the mean). Additionally, the SNPs with a minor allele frequency (MAF) < 0.01, call-rate < 98%, and evidence for violations of Hardy–Weinberg equilibrium (HWE, $P < 1 \times 10^{-5}$) were discarded. Principal component analysis (PCA) was performed with PLINK 2.0, including the genotypes of phase 3 of the 1000 genomes project as reference panel [43]. Individuals not clustering in the PCA with the 1000 genomes subjects of European descent were excluded from further analysis. After imputation the four datasets were merged using only the SNPs with imputation quality (INFO score r^2) higher than 0.7 ($N = 24\,735\,918$ SNPs). The pooled dataset was filtered,

Table 1. Description of the study populations.

	PanScan I, II, III, and PanC4	PanGenEU	PANDoRA	JaPAN ¹	FinnGen ²	Total
Study phase	Discovery	Replication 1	Replication 2	Replication 2	Replication 2	
Number of subjects						
Cases	8738	1317	3442	2039	519	16 055
Controls	7034	1616	3928	32 592	174 006	212 149
Total	15 772	2933	7370	34 631	174 525	235 231
Median age (25%–75% percentiles)						
Cases	65 (55–75)	66 (57–73)	66 (58–73)	62.7 66.3	-	-
Controls	65 (55–75)	65 (55–75)	59 (50–66)	43.6 56.3	-	-
Sex						
Female	46%	42%	47%	-	-	-
Male	54%	58%	53%	-	-	-

¹The information about sex and age are reported as minimum | maximum value.

²We used the FinnGen documentation of R4 Release.

‘-’: Information not available in the original database.

removing the variants with call rate $< 98\%$ ($N = 11\,699\,683$ SNPs), $MAF < 1\%$ ($N = 5\,524\,684$ SNPs), or departure from HWE ($P < 1 \times 10^{-5}$, $N = 2206$ SNPs). The discovery dataset consisted therefore of 8738 PDAC case and 7034 controls that were analysed for 7 509 345 SNPs. The ‘inflation factor’ calculated in each dataset did not show evidence of systematic inflation ($\lambda = 1.000$ for PanScan I, $\lambda = 1.015$ for PanScan II, $\lambda = 1.026$ for PanScan III, $\lambda = 1.000$ for PanC4, and $\lambda = 1.000$ for the aggregate dataset).

Replication phase

In the replication phase, data obtained from four independent populations were analysed, using the summary statistics of three studies: (I) PanGenEU, (II) FinnGen, and (III) JaPAN. Additionally, the SNPs to be validated were genotyped in the PANDoRA consortium. All populations have been described in detail elsewhere [23,24,41,42,44]. A brief description is also given in [Supplementary Material 1](#).

Summary statistics of PanGenEU were used as first replication (Replication 1), then the variants that showed a statistically significant association ($P < .05$) in PanGenEU were genotyped in PANDoRA and looked up in FinnGen and JaPAN (Replication 2) for a total of 7317 cases and 212 142 controls comprised in the four populations.

PANDoRA sample preparation and genotyping

DNA of cases and controls from PANDoRA was extracted from whole blood, using the QIamp[®] 96 DNA QIAcube[®] HT Kit (Qiagen, Hilden, Germany). Genotyping was performed using TaqMan technology (ThermoFisher Applied Biosystems, Waltham MA, USA) in 384-well plates. A similar number of cases and controls was distributed in each plate, and duplicate samples (8%) were added for quality control purposes. Genotypes were determined using the QuantStudio[™] 5 Real-Time PCR system (ThermoFisher, USA).




Figure 1. Flowchart of SNP selection.

Statistical analysis

The association between SNPs and risk of developing PDAC was evaluated through unconditional logistic regression analysis adjusted for sex, age, and the top eight principal components for the discovery phase (PanScan I, II, III, and PanC4) and for sex, age, and country of origin in the replication phase (PANDoRA). All the statistical analyses were conducted using PLINK 2.0 and R software. The details of the statistical analyses adopted in the PanGenEU, JaPAN, and FinnGen GWAS are reported elsewhere [23,41,42]. A meta-analysis was performed for all the variants that showed a statistically significant association in PanGenEU using all the populations (PanScan I, II, III, PanC4, PanGenEU, PANDoRA, JaPAN, and FinnGen). Stratified analysis including only European individuals was also performed to avoid confounding bias due to the different ethnic groups. To account for multiple testing, we considered linkage disequilibrium ($LD r^2 > 0.8$; 1000 genomes, Europeans) among the SNPs used in the discovery phase to obtain a list of independent variants ($N = 37\,435$). The threshold for statistical significance was, therefore, set to $P = .05/37\,435 = 1.34 \times 10^{-6}$ using Bonferroni's correction.

Results

Fig. 1 shows the flowchart of the study design and replication across the populations. During the discovery phase 73 700 unique SNPs associated with at least one human trait were identified in GWAS Catalog and analysed in the Pancreatic Cancer Cohort Consortium (PanScan I, II, and III), and

the Pancreatic Cancer Case-Control Consortium (PanC4) datasets, for a total of 8738 PDAC cases and 7034 controls; 12 728 variants and their LD proxies ($r^2 > 0.8$) were not present in the dataset. Among the 61 052 remaining variants, 428 showed a statistically significant association with PDAC risk ($P < 0.05$) (Supplementary Table S1). Among these, 164 SNPs were in LD ($r^2 > 0.8$) with known PDAC risk loci, and the remaining 264 variants were pruned ($r^2 > 0.6$) to eliminate residual LD and to identify independent SNPs to be validated. The final list of SNPs to be further validated consisted of 113 SNPs (Supplementary Table S1).

These 113 SNPs were tested in PanGenEU, where seven variants showed an association ($P < .05$). One SNP (11p14.2-rs117551578) showed a statistically significant association with the risk of developing PDAC in both the discovery phase and in PanGenEU, but in the opposite direction, therefore it was excluded from the subsequent analyses. Table 2 shows the seven SNPs associated with PanGenEU, their P -value of association with PDAC risk and the P -value of association with the trait for which they were originally selected.

The remaining six SNPs (6q22.32-rs6919397; 8p23.1-rs2980752; 7q36.3-rs288762; 10q21.1-rs4948550; 12q12-rs12427164; and 17q23.2-rs9903801) were analysed in Replication 2 (described in the methods), that included genotypes of PANDoRA and summary statistics from FinnGen and JaPAN and then meta-analysed. None of the SNPs showed a statistically significant association in the studies belonging to Replication 2. Furthermore, the overall meta-analysis,

Table 2. SNPs associated with PDAC risk in discovery phase (PanScan and PanC4) that were found associated also in replication 1 (PanGenEU GWAS).

SNP	Locus	M/m	MAF in CEU	Results of replication 1		Associated traits in GWAS Catalog		
				OR (95%CI)	Pvalue	Traits	OR (95%CI)	P value
rs6919397	6q22.32	T/G	0.409	0.80 (0.69–0.92)	0.002	Neuroticism	NR (NR)	4×10^{-8}
						Type 1 diabetes (rs9388489, $r^2 = 0.99$, $D' = 1.00$) [#]	1.17 (1.10–1.24)	4×10^{-13}
						Type 2 diabetes (rs4897182, $r^2 = 0.97$, $D' = 0.99$) [#]	1.05 (1.02–1.11)	3×10^{-8}
rs288762	7q36.3	C/T	0.384	1.17 (1.01–1.36)	0.034	Estimated glomerular filtration rate in nondiabetics	1.44 (1.11–2.30)	2×10^{-11}
rs2980752	8p23.1	C/A	0.294	0.84 (0.72–0.99)	0.034	Heel bone mineral density	1.03 (1.00–1.07)	3×10^{-50}
rs4948550	10q21.1	C/T	0.328	0.85 (0.73–1.00)	0.049	Triglyceride levels (rs2980755, $r^2 = 0.41$, $D' = 0.91$) [#]	0.98 (0.95–0.99)	1×10^{-10}
						Cardiovascular disease	NR (NR)	7×10^{-8}
rs35138700*	12q12	C/T	0.394	1.18 (1.02–1.37)	0.029	Colorectal cancer (rs4948317, $r^2 = 0.82$, $D' = 0.97$) [#]	1.10 (1.06–1.13)	7×10^{-8}
						Morning person (rs2893787, $r^2 = 0.91$, $D' = 0.99$) [#]	NR (NR)	2×10^{-8}
						Morning person	1.05 (NR)	4×10^{-43}
rs7214227*	17q23.2	C/T	0.146	0.76 (0.63–0.93)	0.014	Type 2 diabetes (rs7315028, $r^2 = 0.57$, $D' = 0.96$) [#]	1.13 (1.04–1.33)	2×10^{-8}
						Estimated glomerular filtration rate	1.01 (1.00–1.01)	2×10^{-36}
						Renal function-related traits (rs11868441, $r^2 = 0.61$, $D' = 0.89$) [#]	1.01 (1.00–1.01)	2×10^{-9}

*SNPs selected as proxy ($r^2 = 1$, $D' \geq 0.94$).

[#]Traits reported in GWAS Catalog for variants in LD ($r^2 > 0.4$) with the SNPs analysed in replication 1.

M/m: major/minor allele; OR (95%CI): odds ratio and its 95% confidence interval; NR: data not reported in GWAS Catalog, the P value refers to the association with the reported trait.

Table 3. Associations between selected SNPs and PDAC risk in the individual studies and in the meta-analysis.

SNP, locus, M/m		PanScan/PanC4	PanGenEU	PANDoRA ¹	PANDoRA ²	JaPAN	FinnGen	Meta-analysis ¹	Meta-analysis ²
rs6919397	OR (95%CI)	0.92 (0.88–0.96)	0.80 (0.69–0.92)	0.98 (0.92–1.05)	0.98 (0.91–1.05)		1.06 (0.93–1.2)	0.94 (0.87–1.02)	0.95 (0.88–1.03)
6q22.32	P_{value}	1.31×10^{-4}	2.44×10^{-3}	6.17×10^{-1}	5.40×10^{-1}		3.84×10^{-1}	1.35×10^{-1}	2.17×10^{-1}
T/G	P_{value} Het.							1.18×10^{-2}	9.70×10^{-3}
rs288762	OR (95%CI)	1.10 (1.05–1.15)	1.17 (1.01–1.36)	1.02 (0.95–1.10)	1.02 (0.95–1.09)	1.02 (0.94–1.11)	1.09 (0.96–1.24)	1.07 (1.04–1.11)	1.08 (1.04–1.12)
7q36.3	P_{value}	1.09×10^{-4}	3.38×10^{-2}	5.04×10^{-1}	6.60×10^{-1}	6.13×10^{-1}	1.79×10^{-1}	3.98×10^{-5}	3.03×10^{-5}
C/T	P_{value} Het.							2.52×10^{-1}	2.13×10^{-1}
rs2980752	OR (95%CI)	0.90 (0.85–0.95)	0.84 (0.72–0.99)	0.98 (0.91–1.05)	0.98 (0.91–1.06)	1.02 (0.95–1.10)	0.97 (0.85–1.10)	0.95 (0.89–1.01)	0.92 (0.89–0.96)
8p23.1	P_{value}	2.92×10^{-4}	3.38×10^{-2}	5.29×10^{-1}	5.40×10^{-1}	5.33×10^{-1}	6.28×10^{-1}	7.98×10^{-2}	1.38×10^{-4}
C/A	P_{value} Het.							2.55×10^{-2}	1.71×10^{-1}
rs4948550	OR (95%CI)	0.91 (0.87–0.96)	0.85 (0.73–1.00)	0.97 (0.89–1.04)	0.95 (0.88–1.03)	0.99 (0.91–1.07)	0.99 (0.86–1.14)	0.94 (0.91–0.97)	0.92 (0.89–0.96)
10q21.1	P_{value}	2.92×10^{-4}	4.99×10^{-2}	3.64×10^{-1}	2.40×10^{-1}	7.74×10^{-1}	8.84×10^{-1}	3.91×10^{-4}	6.52×10^{-5}
C/T	P_{value} Het.							2.58×10^{-1}	4.47×10^{-1}
rs35138700*	OR (95%CI)	1.11 (1.04–1.18)	1.18 (1.02–1.37)	1.01 (0.94–1.09)	1.02 (0.93–1.12)	1.03 (0.93–1.14)	0.91 (0.93–1.20)	1.05 (0.97–1.12)	1.05 (0.96–1.16)
12q12	P_{value}	9.32×10^{-5}	2.86×10^{-2}	7.11×10^{-1}	6.40×10^{-1}	5.29×10^{-1}	1.48×10^{-1}	2.19×10^{-1}	2.92×10^{-1}
C/T	P_{value} Het.							1.24×10^{-2}	1.06×10^{-2}
rs7214227*	OR (95%CI)	0.9 (0.85–0.96)	0.76 (0.63–0.93)	1.03 (0.94–1.14)	1.01 (0.92–1.11)	1.03 (0.93–1.14)	0.92 (0.77–1.10)	0.94 (0.86–1.03)	0.92 (0.88–0.97)
17q23.2	P_{value}	1.14×10^{-3}	6.68×10^{-3}	4.74×10^{-1}	8.60×10^{-1}	5.87×10^{-1}	3.72×10^{-1}	1.93×10^{-1}	8.89×10^{-4}
C/T	P_{value} Het.							1.06×10^{-2}	5.18×10^{-2}

¹Result with all subjects; ² results excluding non-European subjects.

*SNPs selected as proxy ($r^2 = 1$, $D \geq 0.94$).

m = minor allele; M = major allele; P_{value} Het' = P_{value} of heterogeneity. When the studies were heterogeneous, we performed the meta-analysis with the random effect model, while when studies were not heterogeneous, we used the fixed-effect model.

performed including a total of 16 055 PDAC cases and 212 149 controls, did not show any statistically significant association, considering Bonferroni correction for multiple testing (Table 3). Excluding non-European (Brazilian from PANDoRA and Japanese from JAPAN) individuals from the meta-analysis, lower *P*-values compared to the discovery phase were observed for 7q36.3-rs288762 (OR = 1.08, 95%CI = 1.04–1.12, $P = 3.03 \times 10^{-5}$) and for 10q21.1-rs4948550 (OR = 0.92, 95%CI = 0.89–0.96, $P = 6.52 \times 10^{-5}$).

Discussion

Among the six SNPs selected for the replication phase in PANDoRA, JAPAN, and FinnGen, none showed significant associations ($P < .05$) in the studies taken individually; however, 10q21.1-rs4948550 and 7q36.3-rs288762 showed a lower *P*-value in the meta-analysis compared with the discovery phase. In addition, removing individuals of non-European or of admixed ancestry from the analysis, the significance level of the results improved further for 7q36.3-rs288762 ($P_{\text{value}} = 3.03 \times 10^{-5}$) and for 10q21.1-rs4948550 ($P_{\text{value}} = 6.52 \times 10^{-5}$). This improvement could be explained by the fact that the two SNPs are just risk markers, not directly responsible for the disease and, therefore, the presence of a different LD architecture across populations could dilute the results when considering different ethnicities together. The causative SNP could be linked to the markers in central Europeans but not in Asians, or Brazilians, or in LD with a variant that was not genotyped and that is in different LD blocks in the various populations. However, none of the variants reached the *P*-value threshold set for this study, considering the correction for multiple testing ($P = 1.34 \times 10^{-6}$).

The best association was observed for 10q21.1-rs4948550 which is located in the BicC Family RNA Binding Protein 1 (*BICC1*) gene, that encodes an RNA-binding protein that regulates cell proliferation and apoptosis [45]. This SNP is a missense variant that leads to the aminoacidic variation Ser943Pro, for which a benign clinical significance is reported on NCBI dbSNP portal (www.ncbi.nlm.nih.gov). The 10q21.1-rs4948550 region shows a high degree of pleiotropy since the SNP (or the SNPs in LD with it) is associated with cardiovascular disease, bilateral cleft lip, morningness (i.e. the individual preference of waking up early) and colorectal cancer [46–48]. In particular, 10q21.1-rs4948550 is in strong LD with rs4948317 ($r^2=0.82$, $D'=0.98$ in Europeans) which was identified to be associated with risk of colorectal cancer (CRC, $P = 7 \times 10^{-8}$) in a GWAS study carried out in East Asian individuals. The connection between CRC and PDAC is intriguing because the two tumours share several risk loci, for example, 5p15.33-*TERT*, 16q24.1-*LINC01081/LINC00917*, 7p12.3-*TNS3*, and the region of *ABO* on 9q34 [9,12,49–52]. Therefore, the results of our study may suggest another potential pleiotropic locus shared by PDAC and CRC, highlighting the importance of pleiotropy in human neoplastic diseases and a possible overlap in pathways and mechanisms that lead to the development of the two diseases.

The other potentially interesting SNP, 7q36.3-rs288762, is situated 28 558 base pairs upstream of the sonic hedgehog (*SHH*) gene, that is involved in cell differentiation. *SHH* has been observed to be overexpressed in cancer patients, thus creating a favourable environment for metastasis, proliferation, and drug resistance [11,53,54]. Three SNPs located in the *SHH* gene (rs167020, rs172310, and rs288746) are already

known to be associated with the risk of developing PDAC [12], highlighting the importance of the genetic variability of this region in PDAC. These three SNPs are in weak LD with rs288762, ($r^2 < 0.35$ in the European population). This region is particularly interesting due to the different results obtained with cohort and case-control studies. Amundadottir *et al.* observed a strong association for rs167020 ($P = 1.76 \times 10^{-7}$), rs172310 ($P = 2.01 \times 10^{-7}$), and rs288746 ($P = 1.35 \times 10^{-4}$) in prospective cohorts included in PanScan-I, but the associations were not confirmed in the retrospective studies used for replication ($P = .122$, $P = .095$, and $P = .108$, respectively) [12]. Similarly, in our study, 7q36.3-rs288762 was observed to be associated with PDAC risk in the discovery phase ($P = 1.09 \times 10^{-4}$), which included mainly prospective studies, among which those analysed in 2009 by Amundadottir *et al.*, but not in the European retrospective populations used in the replication phase (PanGenEU $P = .03$, PANDoRA $P = .66$ and FinnGen $P = .37$). Interestingly, Regan *et al.* observed that noncanonical expression of *SHH* pathways positively regulates WNT signalling and may be crucial for colon cancer stem cell survival once again highlighting a connection between PDAC and CRC [55]. Moreover, the T allele of rs288762, associated with an increased risk of developing PDAC, is also significantly associated with a low estimated glomerular filtration rate. This trait was already found to be associated with one (rs9903801) of the six SNPs analysed in Replication 2, suggesting a possible correlation between the risk of developing PDAC and a low estimated glomerular filtration rate. Additionally, it is interesting to note that C-reactive protein/albumin ratio is a predictor of pancreatic cancer survival, however, further studies are warranted to characterize the mechanism linking these two traits.

A clear strength of this study is the large sample size, with 16 055 cases of PDAC and 212 149 controls, and a rigorous multi-phase process to eliminate spurious findings.

A possible limitation is the lack of a prospective cohort to replicate the finding on 7q36.2 to shed more light on the association of rs288762, located at this locus, since it appears to have different effect in prospective and retrospective studies. Another possible limitation is the fact that in the FinnGen study, exocrine and endocrine pancreatic cancers are not divided. However, considering the very low prevalence of the latter (less than 2% of all pancreatic cancers), it is unlikely that this would have changed our results.

In conclusion, none of the SNPs showed a formally statistically significant association after correction for multiple testing. However, due to their pleiotropic nature and their connection with CRC, the two SNPs showing the best associations with PDAC risk merit further investigation through fine mapping and ad hoc functional studies.

Supplementary data

Supplementary Table X is available at *Mutagenesis* Online.

Acknowledgements

We would like to acknowledge the contribution of the late Dr Bas Bueno-de-Mesquita. This article/publication is based upon work from COST Action Transpan supported by COST (European Cooperation in Science and Technology). Members of the PanGenEU consortium are listed at [Supplementary Material: Annex S1](#). We would like to thank

Prof. Key T.J. (Epidemiology Unit Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom) and Prof. Wareham N.J. (MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom) and Prof. Vermeulen R.C.H. (University of Utrecht) for the EPIC genotyping data used in the PANDoRA replication. The EPIC-Norfolk study (DOI 10.22025/2019.10.105.00004) has received funding from the Medical Research Council (MR/N003284/1 and MC-UU_12015/1) and Cancer Research UK (C864/A14136). We are grateful to all the participants who have been part of the project and to the many members of the study teams at the University of Cambridge who have enabled this research. The authors would also thank all the participants of the PanScan GWAS Study and Pancreatic Cancer Case Control Association Study, and dbGaP for providing cancer genotyping dataset. For the Humanitas group, the biological material of the individuals included in the study was provided by the Center for Biological Resources at Humanitas Research Hospital.

Author contributions

D.C. conceived and designed the study. M.Gi., M.R., performed the lab work, M.Ge., M.R. analysed the data. All the authors contributed with the interpretation of the data. M.Gi., M.Ge., D.C. wrote the first draft of the manuscript and all authors contributed to the writing and approve of the final version of the manuscript.

Conflict of interest

M.F. Bijlsma. has received research funding from Celgene and LeadPharma, and has acted as a consultant to Servier.

Funding

This work was partially supported by intramural funds of University of Pisa and DKFZ; by Fondazione Tizzi (www.fondazionetizzi.it) and by Fondazione Arpa (www.fondazionearpa.it). Tavano F. was supported by Italian Ministry of Health grants to Fondazione ‘Casa Sollievo della Sofferenza’ IRCCS Hospital, San Giovanni Rotondo (FG), Italy and by the ‘5x1000’ voluntary contribution; by Ministry of Health, Czech Republic, NV19-09-00088 (to Lovecek M.), NV19-03-00097 (to B. Mohelníková-Duchoňová), NV19-08-00113 (to P. Soucek), NU21-07-00247 (to P. Vodicka). G. Capurso received funding from AIRC (IG 2021 ID 26201). The PanGenEU team was supported by Fondo de Investigaciones Sanitarias (FIS), Instituto de Salud Carlos III, Spain (#PI061614, #PI11/01542, #PI0902102, #PI12/01635, #PI12/00815, #PI15/01573, #PI18/01347), Red Temática de Investigación Cooperativa en Cáncer, Spain (#RD12/0036/0034, #RD12/0036/0050, #RD12/0036/0073), EU-6FP Integrated Project (#018771-MOLDIAG-PACA), EU-FP7-HEALTH (#259737-CANCERIALIA, #256974-EPC-TM-Net), Pancreatic Cancer Collective (PCC): Lustgarten Foundation & Stand-Up to Cancer (SU2C #6179).

Ethics statement

Each participating study obtained approval from the responsible institutional review board (IRB) and IRB certification permitting data sharing in accordance with the NIH Policy

for sharing of Data Obtained in NIH-Supported or NIH-Conducted Genome Wide Association Studies. The PANDoRA study protocol was approved by the Ethics Commission of the Medical Faculty of the University of Heidelberg. In accordance with the Declaration of Helsinki, written informed consent was obtained from each participant. IRB ethical approval and written informed consent was obtained by all participating centres contributing to PanGenEU Study. The FinnGen study was approved by the ethical Review Board of the Hospital District of Helsinki and Uusimaa. FinnGen participants provided written, informed consent. For JaPAN, written informed consent was obtained from all study participants, and the study protocol was approved by the Ethical Review Board of Aichi Medical University, the Institutional Ethics Committee of Aichi Cancer Center, the Human Genome and Gene Analysis Research Ethics Committee of Nagoya University, and the ethics committees of all participating hospitals.

Data Availability

The PanScan and PanC4 genotyping data are available from the database of Genotypes and Phenotypes (dbGaP, study accession numbers phs000206.v5.p3 and phs000648.v1.p1). JaPAN data are available from the JaPAN consortium website (www.aichi-med-u.ac.jp/JaPAN). FinnGen summary statistics are available from the FinnGen study website (www.finnngen.fi). The PANDoRA primary data for this work will be made available to researchers who submit a reasonable request to the corresponding author, conditional to approval by the PANDoRA Steering Committee and Ethics Commission of the Medical Faculty of the University of Heidelberg. Data will be stripped from all information allowing identification of study participants. PanGenEU GWAS summary statistics are available in GWAS catalog repository.

References

- Sung H, Ferlay J, Siegel RL, *et al.* Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2021;71:209–49. <https://doi.org/10.3322/caac.21660>
- Maisonneuve C, Guilleret I, Vick P, *et al.* Bicaudal C, a novel regulator of Dvl signaling abutting RNA-processing bodies, controls cilia orientation and leftward flow. *Development (Cambridge, England)* 2009;136:3019–30. <https://doi.org/10.1242/DEV.038174>
- Lu Y, Gentiluomo M, Lorenzo-Bermejo J, *et al.* Mendelian randomisation study of the effects of known and putative risk factors on pancreatic cancer. *J Med Genet* 2020;57:820–8. <https://doi.org/10.1136/jmedgenet-2019-106200>
- Rizzato C, Campa D, Pezzilli R, *et al.* ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium. *Oncol Rep* 2013;29:1637–44. <https://doi.org/10.3892/or.2013.2285>
- Peduzzi G, Felici A, Pellungrini R, *et al.* Analysis of exposome and genetic variability suggests stress as a major contributor for development of pancreatic ductal adenocarcinoma. *Dig Liver Dis* 2023;S1590-8658(23)01004-6. <https://doi.org/10.1016/j.dld.2023.10.015>
- Chang J, Tian J, Zhu Y, *et al.* Exome-wide analysis identifies three low-frequency missense variants associated with pancreatic cancer risk in Chinese populations. *Nat Commun* 2018;9:3688. <https://doi.org/10.1038/s41467-018-06136-x>
- Nakatochi M, Lin Y, Ito H, *et al.* Prediction model for pancreatic cancer risk in the general Japanese population. *PLoS One* 2018;13:e0203386. <https://doi.org/10.1371/journal.pone.0203386>

8. Zhang M, Wang Z, Obazee O, *et al.* Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. *Oncotarget* 2016;7:66328–43. <https://doi.org/10.18632/oncotarget.11041>
9. Wolpin BM, Rizzato C, Kraft P, *et al.* Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. *Nat Genet* 2014;46:994–1000. <https://doi.org/10.1038/ng.3052>
10. Low S-K, Kuchiba A, Zembutsu H, *et al.* Genome-wide association study of pancreatic cancer in Japanese population. *PLoS One* 2010;5:e11824. <https://doi.org/10.1371/journal.pone.0011824>
11. Petersen GM, Amundadottir L, Fuchs CS, *et al.* A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. *Nat Genet* 2010;42:224–8. <https://doi.org/10.1038/ng.522>
12. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, *et al.* Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. *Nat Genet* 2009;41:986–90. <https://doi.org/10.1038/ng.429>
13. Wu C, Miao X, Huang L, *et al.* Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. *Nat Genet* 2011;44:62–6. <https://doi.org/10.1038/ng.1020>
14. Childs EJ, Mocchi E, Campa D, *et al.* Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. *Nat Genet* 2015;47:911–6. <https://doi.org/10.1038/ng.3341>
15. Gentiluomo M, Canzian F, Nicolini A, *et al.* Germline genetic variability in pancreatic cancer risk and prognosis. *Semin Cancer Biol* 2020;79:105–31. <https://doi.org/10.1016/j.semcancer.2020.08.003>
16. Corradi C, Gentiluomo M, Gajdán L, *et al.* Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. *Int J Cancer* 2021;148:2779–88. <https://doi.org/10.1002/ijc.33475>
17. Campa D, Pastore M, Gentiluomo M, *et al.* Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. *Oncotarget* 2016;7:57011–20. <https://doi.org/10.18632/oncotarget.10935>
18. Campa D, Rizzato C, Stolzenberg-Solomon R, *et al.* TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. *Int J Cancer* 2015;137:2175–83. <https://doi.org/10.1002/ijc.29590>
19. Campa D, Matarazzi M, Greenhalf W, *et al.* Genetic determinants of telomere length and risk of pancreatic cancer: a PANDoRA study. *Int J Cancer* 2019;144:1275–83. <https://doi.org/10.1002/ijc.31928>
20. Gentiluomo M, Peduzzi G, Lu Y, *et al.* Genetic polymorphisms in inflammatory genes and pancreatic cancer risk: a two-phase study on more than 14 000 individuals. *Mutagenesis* 2019;34:395–401. <https://doi.org/10.1093/mutage/gez040>
21. Peduzzi G, Gentiluomo M, Tavano F, *et al.* Genetic polymorphisms involved in mitochondrial metabolism and pancreatic cancer risk. *Cancer Epidemiol Biomarkers Prev* 2021;30:2342–5. <https://doi.org/10.1158/1055-9965.EPI-21-0353>
22. Campa D, Gentiluomo M, Obazee O, *et al.* Genome-wide association study identifies an early onset pancreatic cancer risk locus. *Int J Cancer* 2020;147:2065. <https://doi.org/10.1002/ijc.33004>
23. López de Maturana E, Rodríguez JA, Alonso L, *et al.*; PanGenEU Investigators. A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. *Genome Med* 2021;13:15. <https://doi.org/10.1186/s13073-020-00816-4>
24. Campa D, Gentiluomo M, Stein A, *et al.* The PANcreatic Disease ReseArch (PANDoRA) consortium: ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. *Crit Rev Oncol Hematol* 2023;186:104020.
25. Lindström S, Finucane H, Bulik-Sullivan B, *et al.*; PanScan, GECCO and the GAME-ON Network: CORECT, DRIVE, ELLIPSE, FOCI, and TRICL-ILCCO. Quantifying the genetic correlation between multiple cancer types. *Cancer Epidemiol Biomarkers Prev* 2017;26:1427–35. <https://doi.org/10.1158/1055-9965.EPI-17-0211>
26. Rashkin SR, Graff RE, Kachuri L, *et al.* Pan-cancer study detects genetic risk variants and shared genetic basis in two large cohorts. *Nat Commun* 2020;11:1–14. <https://doi.org/10.1038/s41467-020-18246-6>
27. Loos RJF. 15 years of genome-wide association studies and no signs of slowing down. *Nat Commun* 2020;11:1–3. <https://doi.org/10.1038/s41467-020-19653-5>
28. Sivakumaran S, Agakov F, Theodoratou E, *et al.* Abundant pleiotropy in human complex diseases and traits. *Am J Hum Genet* 2011;89:607–18. <https://doi.org/10.1016/j.ajhg.2011.10.004>
29. Gratten J, Visscher PM. Genetic pleiotropy in complex traits and diseases: implications for genomic medicine. *Genome Med* 2016;8:1–3. <https://doi.org/10.1186/S13073-016-0332-X>
30. Solovieff N, Cotsapas C, Lee PH, *et al.* Pleiotropy in complex traits: challenges and strategies. *Nat Rev Genet* 2013;14:483–95. <https://doi.org/10.1038/nrg3461>
31. Fehrer G, Kraft P, Pharoah PD, *et al.*; Ovarian Cancer Association Consortium (OCAC). Cross-cancer genome-wide analysis of lung, ovary, breast, prostate, and colorectal cancer reveals novel pleiotropic associations. *Cancer Res* 2016;76:5103–14. <https://doi.org/10.1158/0008-5472.CAN-15-2980>
32. Chung CC, Chanock SJ. Current status of genome-wide association studies in cancer. *Hum Genet* 2011;130:59–78. <https://doi.org/10.1007/s00439-011-1030-9>
33. Crocco P, Barale R, Rose G, *et al.* Population-specific association of genes for telomere-associated proteins with longevity in an Italian population. *Biogerontology* 2015;16:353–64. <https://doi.org/10.1007/s10522-015-9551-6>
34. Bonàs-Guarch S, Guindo-Martínez M, Miguel-Escalada I, *et al.* Re-analysis of public genetic data reveals a rare X-chromosomal variant associated with type 2 diabetes. *Nat Commun* 2018;9:321. <https://doi.org/10.1038/s41467-017-02380-9>
35. Gentiluomo M, Luddi A, Cingolani A, *et al.* Telomere length and male fertility. *Int J Mol Sci* 2021;22:3959. <https://doi.org/10.3390/ijms22083959>
36. Chong M, Mohammadi-Shemirani P, Perrot N, *et al.* GWAS and ExWAS of blood mitochondrial DNA copy number identifies 71 loci and highlights a potential causal role in dementia. *eLife* 2022;11:e70382. <https://doi.org/10.7554/eLife.70382>
37. Richardson TG, Sanderson E, Palmer TM, *et al.* Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. *PLoS Med* 2020;17:e1003062. <https://doi.org/10.1371/journal.pmed.1003062>
38. Pierce BL, Ahsan H. Genome-wide 'Pleiotropy Scan' Identifies HNF1A region as a novel pancreatic cancer susceptibility locus. *Cancer Res* 2011;71:4352–8. <https://doi.org/10.1158/0008-5472.CAN-11-0124>
39. Molina-Montes E, Coscia C, Gómez-Rubio P, *et al.*; PanGenEU Study Investigators. Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses. *Gut* 2021;70:319–29. <https://doi.org/10.1136/gutjnl-2019-319990>
40. Nagai A, Hirata M, Kamatani Y, *et al.*; BioBank Japan Cooperative Hospital Group. Overview of the BioBank Japan Project: study design and profile. *J Epidemiol* 2017;27:S2–8. <https://doi.org/10.1016/j.je.2016.12.005>
41. Lin Y, Nakatochi M, Hosono Y, *et al.* Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer. *Nat Commun* 2020;11:3175. <https://doi.org/10.1038/s41467-020-16711-w>
42. Kurki MI, Karjalainen J, Palta P, *et al.* FinnGen provides genetic insights from a well-phenotyped isolated population. *Nature* 2023;613:508–18. <https://doi.org/10.1038/s41586-022-05473-8>
43. Abecasis GR, Altshuler D, Auton A, *et al.*; 1000 Genomes Project Consortium. A map of human genome variation from

- population-scale sequencing. *Nature* 2010;467:1061–73. <https://doi.org/10.1038/nature09534>
44. Campa D, Rizzato C, Capurso G, et al. Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. *Dig Liver Dis* 2013;45:95–9. <https://doi.org/10.1016/j.dld.2012.09.014>
 45. Zhao R, Peng C, Song C, et al. BICC1 as a novel prognostic biomarker in gastric cancer correlating with immune infiltrates. *Int Immunopharmacol* 2020;87:106828. <https://doi.org/10.1016/j.intimp.2020.106828>
 46. Jones SE, Lane JM, Wood AR, et al. Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms. *Nat Commun* 2019;10:343. <https://doi.org/10.1038/s41467-018-08259-7>
 47. Kichaev G, Bhatia G, Loh P-R, et al. Leveraging polygenic functional enrichment to improve GWAS power. *Am J Hum Genet* 2019;104:65–75. <https://doi.org/10.1016/j.ajhg.2018.11.008>
 48. Zhang B, Jia W-H, Matsuda K, et al; Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO). Large-scale genetic study in East Asians identifies six new loci associated with colorectal cancer risk. *Nat Genet* 2014;46:533–42. <https://doi.org/10.1038/ng.2985>
 49. Zhang B-L, He N, Huang Y-B, et al. ABO blood groups and risk of cancer: a systematic review and meta-analysis. *Asian Pac J Cancer Prev* 2014;15:4643–50. <https://doi.org/10.7314/apjcp.2014.15.11.4643>
 50. Schmit SL, Edlund CK, Schumacher FR, et al. Novel common genetic susceptibility loci for colorectal cancer. *J Natl Cancer Inst* 2019;111:146–57. <https://doi.org/10.1093/jnci/djy099>
 51. Klein AP, Wolpin BM, Risch HA, et al. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. *Nat Commun* 2018;9:1–11. <https://doi.org/10.1038/s41467-018-02942-5>
 52. Law PJ, Timofeeva M, Fernandez-Rozadilla C, et al; PRACTICAL consortium. Association analyses identify 31 new risk loci for colorectal cancer susceptibility. *Nat Commun* 2019;10:2154. <https://doi.org/10.1038/s41467-019-09775-w>
 53. Jeng KS, Chang CF, Lin SS. Sonic hedgehog signaling in organogenesis, tumors, and tumor microenvironments. *Int J Mol Sci* 2020;21:758. <https://doi.org/10.3390/ijms21030758>
 54. Li X, Ma Q, Duan W, et al. Paracrine sonic hedgehog signaling derived from tumor epithelial cells: a key regulator in the pancreatic tumor microenvironment. *Crit Rev Eukaryot Gene Expr* 2012;22:97–108. <https://doi.org/10.1615/CritRevEukarGeneExpr.v22.i2.20>
 55. Zhao X, Cao D, Ren Z, et al. Dipeptidyl peptidase like 6 promoter methylation is a potential prognostic biomarker for pancreatic ductal adenocarcinoma. *Biosci Rep* 2020;40:BSR20200214. <https://doi.org/10.1042/BSR20200214>